(IBDQ) iShares iBonds Dec 2025 - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46434VBD10 • Target Maturity

IBDQ: Corporate Bonds, Fixed Income Securities

The iShares iBonds Dec 2025 Term Corporate ETF (IBDQ) is a fixed-income ETF designed for investors seeking exposure to U.S. dollar-denominated, investment-grade corporate bonds with a specific maturity range. The fund adheres to a strict investment policy, allocating at least 80% of its assets to the component securities of its underlying index and at least 90% to fixed-income securities of the types included in that index. This structure ensures a high level of alignment with the targeted bond universe.

The underlying index tracks U.S. corporate bonds that are set to mature between January 1, 2025, and December 15, 2025. This bullet maturity approach means the ETF is designed to hold bonds until they mature, providing investors with a predictable return of principal, assuming no defaults. The funds focus on investment-grade bonds (rated BBB- or higher by major rating agencies) emphasizes credit quality, though it does not guarantee protection against credit losses.

As a target maturity ETF, IBDQ is structured similarly to a bond ladder but with the added efficiency of an ETF wrapper. This allows investors to gain diversified exposure to a portfolio of bonds without directly purchasing individual securities. The funds maturity date aligns with the bonds it holds, meaning it will gradually shift into shorter-duration instruments as it approaches December 2025, reducing reinvestment risk over time.

For investors, IBDQ offers a way to add predictability to a fixed-income portfolio, particularly for those seeking to align their investment horizon with the ETFs maturity date. However, like all bond ETFs, it is sensitive to changes in interest rates, and its price can fluctuate prior to maturity. Additionally, while the fund focuses on investment-grade bonds, credit risk remains a consideration, especially in periods of economic uncertainty.

The ETF is managed by BlackRock, the parent company of iShares, and has an AUM of approximately $3.18 billion as of the latest data. It is listed on the NYSE ARCA under the ticker symbol IBDQ and is domiciled in the United States. For more details, investors can visit the iShares website at http://www.ishares.com.

Additional Sources for IBDQ ETF

IBDQ ETF Overview

Market Cap in USD 3,198m
Category Target Maturity
TER 0.10%
IPO / Inception 2015-03-11

IBDQ ETF Ratings

Growth 5y 41.8%
Fundamental -
Dividend 64.6%
Rel. Strength Industry -2.6
Analysts -
Fair Price Momentum 24.43 USD
Fair Price DCF -

IBDQ Dividends

Dividend Yield 12m 3.57%
Yield on Cost 5y 4.14%
Annual Growth 5y 6.80%
Payout Consistency 94.9%

IBDQ Growth Ratios

Growth Correlation 3m 99.7%
Growth Correlation 12m 99.9%
Growth Correlation 5y 19.4%
CAGR 5y 3.24%
CAGR/Max DD 5y 0.34
Sharpe Ratio 12m 8.04
Alpha 1.20
Beta 0.01
Volatility 1.13%
Current Volume 379k
Average Volume 20d 421.3k
What is the price of IBDQ stocks?
As of March 14, 2025, the stock is trading at USD 25.10 with a total of 379,004 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +0.33%, over three months by +1.08% and over the past year by +5.43%.
Is iShares iBonds Dec 2025 a good stock to buy?
Partly, yes. Based on ValueRay Analyses, iShares iBonds Dec 2025 (NYSE ARCA:IBDQ) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.75 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBDQ as of March 2025 is 24.43. This means that IBDQ is currently overvalued and has a potential downside of -2.67%.
Is IBDQ a buy, sell or hold?
iShares iBonds Dec 2025 has no consensus analysts rating.
What are the forecast for IBDQ stock price target?
According to ValueRays Forecast Model, IBDQ iShares iBonds Dec 2025 will be worth about 26.4 in March 2026. The stock is currently trading at 25.10. This means that the stock has a potential upside of +5.1%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 26.4 5.1%